BLT 0.00% 2.6¢ benitec biopharma limited

Great post Bobby. I wonder how much position-building we’ll see...

  1. 89 Posts.
    lightbulb Created with Sketch. 2
    Great post Bobby. I wonder how much position-building we’ll see ahead of John Rossi’s presentation.

    Prof Rossi is also presenting at the ESF-EMBO (European Science Foundation - European Molecular Biology Organisation) "Antiviral Applications of RNA Interference" research conference to be held in Spain 5-10 April 2008.

    "John Rossi City of Hope Beckman Research Institute, US RNAi and combinatorial gene therapy for HIV in hematopoietic stem cell and T-cell gene therapy settings"

    http://www.esf.org/fileadmin/be_user/activities/research_conferences/Docs_NEW/2008/2008-254pp.pdf

    He’s also presenting at the Beyond Genome conference in San Francisco on 11th June:

    9:20 Strategies for RNAi-Based Therapies for the Treatment of HIV Infection
    John Rossi, Ph.D., Professor and Chair, Molecular Biology, Beckman Research Institute of the City of Hope
    We have been exploiting two different but complementary RNAi-based approaches for the therapeutic treatment of HIV infection. The first uses promoter expressed RNAi triggers delivered to hematopoietic cells by lentiviral vector transduction. Our second strategy relies upon anti HIV envelope targeting aptamers to deliver siRNAs targeting HIV into HIV infected cells. This dual inhibitory approach can be used to multiplex siRNAs and aptamers for potent inhibition of HIV replication and spread.

    http://www.beyondgenome.com/08rnx_day2.asp
 
watchlist Created with Sketch. Add BLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.